PPARα Between Aspirin and Plaque Clearance

Area of Science:

• Neuroscience
• Cell Biology
• Pharmacology

Background:

• Impaired amyloid-β (Aβ) clearance is linked to Alzheimer's disease (AD) pathology.
• The lysosome-autophagy network is crucial for degrading protein aggregates and maintaining cell health.
• Targeting cellular degradative pathways for Aβ removal is a key area in AD research.

Purpose of the Study:

• To review the emerging role of aspirin in stimulating cellular clearance mechanisms relevant to AD.
• To elucidate the molecular pathways through which aspirin promotes amyloid plaque removal.

Main Methods:

• Literature review of studies investigating aspirin's effects on lysosomal and autophagy pathways.
• Analysis of molecular mechanisms, including transcription factor EB (TFEB) and peroxisome proliferator-activated receptor alpha (PPARα).

Main Results:

• Low-dose aspirin was found to stimulate lysosomal biogenesis and autophagy.
• Aspirin treatment led to the clearance of amyloid plaques in an animal model of AD.
• The mechanism involves PPARα-mediated transcription of TFEB, a master regulator of lysosomal biogenesis.

Conclusions:

• Aspirin, at low doses, demonstrates a novel therapeutic potential for Alzheimer's disease by enhancing Aβ clearance.
• The findings highlight the importance of the PPARα-TFEB pathway in mediating aspirin's beneficial effects.
• Further research into aspirin's mechanism could lead to new AD treatment strategies.